Skip to main content

Table 3 Subjects with Adverse Events: Incidence Rate ≥ 5%* (two or more subjects)

From: Subcutaneously administered Menopur(R), a new highly purified human menopausal gonadotropin, causes significantly fewer injection site reactions than Repronex(R) in subjects undergoing in vitro fertilization

Adverse Event Menopur® n = 61 Repronex® n = 64
Abdominal cramps 13 (21.3) 14 (21.9)
Headache 13 (21.3) 13 (20.3)
Post retrieval pain 7 (11.5) 9 (14.1)
Nausea 6 (9.8) 10 (15.6)
Vaginal spotting 6 (9.8) 5 (7.8)
Abdominal fullness 5 (8.2) 7 (10.9)
Abdominal pain 5 (8.2) 4 (6.3)
Constipation 5 (8.2) 1 (1.6)
Respiratory disorder 4 (6.6) 4 (6.3)
Vaginal hemorrhage 2 (3.3) 4 (6.3)
Breast tenderness/pain 2 (3.3) 5 (7.8)
Malaise 2 (3.3) 4 (6.3)
Sinusitis 2 (3.3) 4 (6.3)
  1. *Values represent numbers (percentage) of subjects with adverse event.